mail2

Spectrum Library

Home / Spectrum / Rituximab in Neuromyelitis Optica Spectrum Disorders-Reply: Why Not as First-Line Therapy.

Rituximab in Neuromyelitis Optica Spectrum Disorders-Reply: Why Not as First-Line Therapy.

JAMA Neurol. 2017 Apr 1;74(4):482-483. doi: 10.1001/jamaneurol.2016.5936.

Damato V1, Evoli A1, Iorio R2.

Join the Discussion

sandra reeve says:

PLEASE HELP – I AM HAVING DIFFICULTY ACCESSING THIS ARTICLE.
Rituximab in Neuromyelitis Optica Spectrum Disorders-Reply: Why Not as First-Line Therapy.

Hi Sandra,

This post has been updated to include the link to the scientific article.

Leave a Comment

NMO News.

Subscribe to get the latest in news about neuromyelitis optica, from advocacy events to research.

No Thanks